Approximately 1 in 100 (or up to 1 in 50) people prescribed statins develop type 2 diabetes as a result of the medication.
"What else do statins do? They cause insulin resistance. Say 1 in 100 people get type 2 diabetes because of statins. ... Some some studies say 1 in 50, right? Will get type 2 diabetes because of the statin." (said at 0:49:46)
The claim that 1 in 100 (or up to 1 in 50) people develop type 2 diabetes because of statins overstates the excess risk attributable to the medication. In large collaborative meta-analyses of randomized controlled trials, statin therapy was associated with a modest 9% relative increase in incident diabetes (odds ratio 1.09), corresponding to an absolute risk of 1 additional case of diabetes for every 255 patients treated over an average of 4 years (approximately 1 in 255, or ~0.4%). Even when comparing intensive-dose statin therapy to moderate-dose therapy, the number needed to harm per year was 498 (approximately 2.0 additional cases per 1,000 patient-years).
- contradicts: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin … (Lancet (London, England) 2010)
"Statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials... Treatment of 255 (95% CI 150-852) patients with statins for 4 years resulted in one extra case of diabetes." (abstract, results)
pubmedfull study (doi) - contradicts: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: … (JAMA 2011)
"In 5 statin trials with 32,752 participants without diabetes at baseline, 2749 developed diabetes (1449 assigned intensive-dose therapy, 1300 assigned moderate-dose therapy, representing 2.0 additional cases in the intensive-dose group per 1000 patient-years)... As compared with moderate-dose statin therapy, the number needed to harm per year for intensive-dose statin therapy was 498 for new-onset diabetes" (abstract, results, passage verified)
pubmedfull study (doi)